SCHEMBL4337791

SCHEMBL4337791

C[C@@H](NC(=O)CC(=O)N[C@H](C)C(O)(Cc1ccccc1)Cc1ccccc1)C(O)(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
POLB P06746 1/20 0.43
ALDH1A1 P00352 2/20 0.42
HPGD P15428 1/20 0.42
CNR2 P34972 2/20 0.42
TRPA1 O75762 1/20 0.41
CYP1A2 P05177 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP3A4 P08684 1/20 0.41
RECQL P46063 1/20 0.41
HIF1A Q16665 1/20 0.41
PSMB8 P28062 1/20 0.40
PSMB5 P28074 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4341850 0.88 NPC1 (0.46) NPC1RAB9APOLBALDH1A1HPGD
SCHEMBL4340539 0.84 TRPA1 (0.42) NPC1RAB9APOLBALDH1A1TRPA1
SCHEMBL4344035 0.84 TRPA1 (0.42) NPC1RAB9APOLBALDH1A1HPGD
SCHEMBL4333077 0.83 PSMB8 (0.47) NPC1RAB9AALDH1A1CNR2PSMB8
SCHEMBL4343607 0.81 TRPA1 (0.42) NPC1RAB9AALDH1A1CNR2TRPA1
SCHEMBL1152959 0.80 ALDH1A1 (0.40) NPC1RAB9APOLBALDH1A1TRPA1
SCHEMBL11101887 0.79 TAAR1 (0.47) NPC1RAB9APOLBTRPA1CYP1A2
SCHEMBL4348972 0.79 MME (0.45) NPC1RAB9AALDH1A1CYP1A2SMN1; SMN2
SCHEMBL4340482 0.79 CNR2 (0.46) ALDH1A1HPGDCNR2SMN1; SMN2MEN1
SCHEMBL1153786 0.78 ALDH1A1 (0.41) NPC1RAB9AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612236-B2 Method for producing optically active bisamidoalcohol compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-11-03 US disclosed
US-20070100163-A1 Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced SUMITOMO CHEMICAL COMPANY, LIMITED 2007-05-03 US disclosed
EP-1698616-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE BISAMIDO ALCOHOL COMPOUND Sumitomo Chemical Company, Limited (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070100163-A1 Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced CCNL2, ARL1, ACSL3 NPC1 3582/4885RAB9A 1472/4885POLB 1550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.